This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

American Society Of Hematology Announces First Recipients Of Bridge Grants To Support Critical Blood Disease Research During Current Period Of Funding Restrictions

The first round of ASH's one-year, $100,000 bridge grants awarded today will allow 17 basic, clinical, and translational hematology researchers whose NIH R01 series grant applications were deemed excellent by NIH peer review but not funded due to budget cutbacks to continue their critical research on blood diseases. The Society will award at least 30 bridge grants each year over the next three years to help support recipients as they work to secure funding to allow their critical research to move forward.

Research supported by ASH's inaugural round of bridge grants spans the breadth of hematology. Funded projects range from exploring a gene signaling pathway that will allow researchers to better understand chemotherapy resistance in children with acute myeloid leukemia to exploring how red blood cells respond to oxidative stress. Other projects to receive ASH bridge grant funding include studies that seek to gain additional insight into the behavior of gene signaling in lymphoma, the role of a critical marker of blood-forming stem cells, and how proteins when modified induce dangerous arterial blood clots which are a leading cause of acute coronary syndrome and cardiovascular death.

The awards announced today represent the first of two award cycles to occur this year. The second 2013 application deadline will be April 19, and applicants will be notified of acceptance on or around July 1. Beyond the Society's financial commitment that will provide for two rounds of approximately 15 bridge grants to be awarded annually through 2015, additional awards will be supplemented by support from corporate and individual contributors. Generous support from Amgen, Atlanta Convention & Visitors Bureau, Genentech, GlaxoSmithKline, Millennium: The Takeda Oncology Company, and Novartis enabled the Society to award several additional Bridge Grants as part of this first round.

The "Rally for Medical Research," backed by more than 200 partner organizations across the country, serves as a unified call to action to researchers, clinicians, patients, and other advocates to raise awareness of the need for sustained investment in the NIH to improve health, spur more progress, inspire more hope, and save more lives. ASH's support of the rally is one of many components of a multifaceted approach the Society launched last year to address devastating NIH budget cuts, which included the establishment of the Bridge Grant program, the creation of the ASH Foundation, enhanced advocacy, and increased communication to the media about the importance of federally funded biomedical research and to the ASH membership to encourage everyone to join the effort and make their voices heard.

"Through ASH's support of these 17 tremendous research projects as well as our leading role in today's 'Rally for Medical Research' we hope to convey a loud, clear message that this is time to invest – not to defund – science," said Dr. Abkowitz. "We will continue working hard to urge Congress to develop a balanced approach to deficit reduction that does not involve further cuts to biomedical research."

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs